Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan

被引:0
|
作者
Hung, Fei-Hung [1 ]
Peng, Hung-Pin [2 ]
Hung, Chen-Fang [3 ]
Hsieh, Ling-Ling [4 ]
Yang, An-Suei [5 ]
Wang, Yong Alison [4 ,6 ]
机构
[1] Taipei Med Univ, Hlth Data Analyt & Stat Ctr, Off Data Sci, Taipei, Taiwan
[2] Acad Sinica, Biomed Translat Res Ctr, Taipei, Taiwan
[3] Koo Fdn Sun Yat Sen Canc Ctr, Dept Res, Taipei, Taiwan
[4] Koo Fdn Sun Yat Sen Canc Ctr, Dept Internal Med, 125 Lih Der Rd, Taipei 11259, Taiwan
[5] Acad Sinica, Genom Res Ctr, Taipei, Taiwan
[6] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
关键词
cancer risk management; genetic counseling; Lynch syndrome; MMR mutation risk prediction; NONPOLYPOSIS COLORECTAL-CANCER; INTERNATIONAL-COLLABORATIVE-GROUP; MISMATCH-REPAIR GENES; GERMLINE MUTATIONS; ENDOMETRIAL CANCER; CLINICAL-CRITERIA; PREMM5; MODEL; IDENTIFICATION; HNPCC; RISK;
D O I
10.1002/ijc.35106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Identifying Lynch syndrome significantly impacts cancer risk management, treatment, and prognosis. Validation of mutation risk predictive models for mismatch repair (MMR) genes is crucial for guiding genetic counseling and testing, particularly in the understudied Asian population. We evaluated the performance of four MMR mutation risk predictive models in a Chinese cohort of 604 patients with colorectal cancer (CRC), endometrial cancer (EC), or ovarian cancer (OC) in Taiwan. All patients underwent germline genetic testing and 36 (6.0%) carried a mutation in the MMR genes (MLH1, MSH2, MSH6, and PMS2). All models demonstrated good performance, with area under the receiver operating characteristic curves comparable to Western cohorts: PREMM5 0.80 (95% confidence interval [CI], 0.73-0.88), MMRPro 0.88 (95% CI, 0.82-0.94), MMRPredict 0.82 (95% CI, 0.74-0.90), and Myriad 0.76 (95% CI, 0.67-0.84). Notably, MMRPro exhibited exceptional performance across all subgroups regardless of family history (FH+ 0.88, FH- 0.83), cancer type (CRC 0.84, EC 0.85, OC 1.00), or sex (male 0.83, female 0.90). PREMM5 and MMRPredict had good accuracy in the FH+ subgroup (0.85 and 0.82, respectively) and in CRC patients (0.76 and 0.82, respectively). Using the ratio of observed and predicted mutation rates, MMRPro and PREMM5 had good overall fit, while MMRPredict and Myriad overestimated mutation rates. Risk threshold settings in different models led to different positive predictive values. We suggest a lower threshold (5%) for recommending genetic testing when using MMRPro, and a higher threshold (20%) when using PREMM5 and MMRPredict. Our findings have important implications for personalized mutation risk assessment and counseling on genetic testing.
引用
收藏
页码:2201 / 2210
页数:10
相关论文
共 48 条
  • [41] Immunohistochemistry (IHC) as first-line screening tool for detecting colorectal cancer (CRC) patients at risk for Lynch syndrome: A 2-antibody panel is as predictive as a 4-antibody panel
    Shia, J.
    Vakiani, E.
    Guillem, J.
    Tang, L.
    Paty, P.
    Offit, K.
    Klimstra, D.
    MODERN PATHOLOGY, 2008, 21 : 135A - 136A
  • [42] Immunohistochemistry (IHC) as first-line screening tool for detecting colorectal cancer (CRC) patients at risk for Lynch syndrome: A 2-antibody panel is as predictive as a 4-antibody panel
    Shia, J.
    Vakiani, E.
    Guillen, J.
    Tang, L.
    Paty, P.
    Offit, K.
    Klimstra, D.
    LABORATORY INVESTIGATION, 2008, 88 : 135A - 136A
  • [43] Different mutations in the MMUT gene are associated with the effect of vitamin B12 in a cohort of 266 Chinese patients with mut-type methylmalonic acidemia: A retrospective study
    Yu, Yue
    Shuai, Ruixue
    Liang, Lili
    Qiu, Wenjuan
    Shen, Linghua
    Wu, Shengnan
    Wei, Haiyan
    Chen, Yongxing
    Yang, Chiju
    Xu, Peng
    Chen, Xigui
    Zou, Hui
    Feng, Jizhen
    Niu, Tingting
    Hu, Haili
    Ye, Jun
    Zhang, Huiwen
    Lu, Deyun
    Gong, Zhuwen
    Zhan, Xia
    Ji, Wenjun
    Gu, Xuefan
    Han, Lianshu
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2021, 9 (11):
  • [44] Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
    Wen, Miaomiao
    Wang, Xuejiao
    Sun, Ying
    Xia, Jinghua
    Fan, Liangbo
    Xing, Hao
    Zhang, Zhipei
    Li, Xiaofei
    ONCOTARGETS AND THERAPY, 2016, 9 : 1989 - 1995
  • [45] Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
    Lin, D.
    Xi, Y.
    Meng, H.
    Feng, Q.
    Lian, S.
    Gao, N.
    Guo, J.
    Yang, X.
    Deng, S.
    Li, M.
    Gai, F.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S722 - S723
  • [46] Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients
    Liu, Qing-Feng
    Zhang, Zhi-Fei
    Hou, Guang-Jie
    Yang, Guang-Yu
    He, Yi
    BMJ OPEN, 2017, 7 (08):
  • [47] Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).
    Rosas Camargo, Vanessa
    Arteaga, Jazmin
    Melchor Ruan, Javier
    Escorza, Salvador
    Cedro-Tanda, Alberto
    Vidal, Silvia
    Torres Valdiviezo, Lucero Itzel
    Cisneros Cordero, Miriam Heidi
    Arce Sandoval, Cesar
    Meneses Medina, Monica Isabel
    Herrera, Marytere
    Huitzil Melendez, Fidel David David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept
    Zhu, Yan-juan
    Zhang, Hai-bo
    Liu, Li-rong
    Liu, Yi-hong
    Zhang, Fu-li
    Bai, Jian-ping
    Li, Yong
    Qu, Yan-chun
    Qu, Xin
    Chen, Xian
    Li, Yan
    Luo, Shu-yi
    Ou, Ai-hua
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 2017